| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8771952 | The Journal of Urology | 2017 | 25 Pages |
Abstract
Chemotherapy naïve men with metastatic castration resistant prostate cancer and low baseline prostate specific antigen irrespective of disease burden may benefit from enzalutamide. This indicates that targeting the androgen receptor signaling pathway is a therapeutic option in similar patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Mary-Ellen Taplin, Andrew J. Armstrong, Ping Lin, Andrew Krivoshik, De Phung, Teresa Parli, Bertrand Tombal, Tomasz M. Beer,